4 news items
FibroGen Reports First Quarter 2024 Financial Results
FGEN
6 May 24
PET biomarker. In addition, FibroGen has expanded its research and development portfolio to include two immuno-oncology product candidates
FibroGen to Report First Quarter 2024 Financial Results
FGEN
29 Apr 24
biomarker. In addition, FibroGen has expanded its research and development portfolio to include two immuno-oncology product candidates for the treatment
FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology Annual Meeting
FGEN
24 Apr 24
biomarker. In addition, FibroGen has expanded its research and development portfolio to include two immuno-oncology product candidates for the treatment
FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer
FGEN
2 Apr 24
. In addition, FibroGen has expanded its research and development portfolio to include two immuno-oncology product candidates for the treatment of solid tumors
- Prev
- 1
- Next